Clinical Trial Update: Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating levorphanol as a second-line opioid for cancer pain has been terminated; no results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematologic Malignancy
• Solid Tumor Cancer

Drugs mentioned

• Levorphanol (levorphanol)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | EARLY_Phase 1 | Status: TERMINATED